Effects of BAYm 1099, new alpha-glucosidase inhibitor, on acute metabolic responses and metabolic control in NIDDM over 1 mo.

Samad, A H

Effects of BAYm 1099, new alpha-glucosidase inhibitor, on acute metabolic responses and metabolic control in NIDDM over 1 mo. [electronic resource] - Diabetes care Apr 1988 - 337-44 p. digital

Publication Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial

0149-5992

10.2337/diacare.11.4.337 doi


1-Deoxynojirimycin--analogs & derivatives
3-Hydroxybutyric Acid
Alanine--blood
Blood Glucose--metabolism
Clinical Trials as Topic
Diabetes Mellitus, Type 2--blood
Eating
Fatty Acids, Nonesterified--blood
Female
Glucosamine--analogs & derivatives
Glycerol--blood
Glycoside Hydrolase Inhibitors
Humans
Hydroxybutyrates--blood
Hypoglycemic Agents--therapeutic use
Imino Pyranoses
Insulin--blood
Lactates--blood
Male
Middle Aged
Pyruvates--blood